Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JBH492 |
Synonyms | |
Therapy Description |
JBH492 is an antibody-drug conjugate consisting of an antibody that targets CC chemokine receptor 7 present on tumor cells and conjugated to the maytanisoid DM4, which may lead to inhibition of tumor cell proliferation (NCI Drug Ductionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JBH492 | JBH 492|JBH-492|Anti-CCR7 ADC JBH492 | JBH492 is an antibody-drug conjugate consisting of an antibody that targets CC chemokine receptor 7 present on tumor cells and conjugated to the maytanisoid DM4, which may lead to inhibition of tumor cell proliferation (NCI Drug Ductionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04240704 | Phase I | JBH492 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | Terminated | ISR | FIN | ESP | DEU | 3 |